Merck Announces Top-Line Results From Phase 3 Trials Evaluating Gefapixant For Refractory Of Unexplained Chronic Cough; Gefapixant Demonstrated Statistically Significant Decrease In 24-Hour Coughs Per Hour Compared To Placebo At Week 12 And 24
Benzinga Newsdesk